Imeglimin

Imeglimin (brand names like Imeglyn) is an oral medication mainly used to manage Type 2 Diabetes Mellitus (T2DM), working by improving the body’s insulin response, boosting insulin release, reducing liver sugar production, and enhancing insulin sensitivity in muscles, complementing diet and exercise to control blood sugar. It’s a novel drug that acts uniquely by targeting mitochondrial function in cells, improving energy use and protecting pancreatic cells, potentially offering benefits beyond glucose control, including vascular health. It is grouped under the following drug class(es): Hypoglycemics. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include imegliminum, (6R)-N4, N4, 6-trimethyl-1, 6-dihydro-1, 3, 5-triazine-2 and 4-diamine. Its PubChem CID is 24812808.